PFIZER INC Proceeds from Stock Options Exercised
PFIZER INC (PFE) reported Proceeds from Stock Options Exercised of $425.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2021-02-25
- PFIZER INC proceeds from stock options exercised for the quarter ending 2020-12-31 was $219.00M, a 140.66% increase year-over-year.
- PFIZER INC proceeds from stock options exercised for the quarter ending 2020-09-27 was $48.00M, a 12.73% decline year-over-year.
- PFIZER INC proceeds from stock options exercised for the quarter ending 2020-06-28 was $34.00M, a 72.13% decline year-over-year.
- PFIZER INC proceeds from stock options exercised for the quarter ending 2020-03-29 was $124.00M, a 1.59% decline year-over-year.
- PFIZER INC proceeds from stock options exercised for fiscal 2020 was $425.00M, a 7.87% increase from fiscal 2019.
- PFIZER INC proceeds from stock options exercised for fiscal 2019 was $394.00M, a 68.71% decline from fiscal 2018.
- PFIZER INC proceeds from stock options exercised for fiscal 2018 was $1.26B, a 46.06% increase from fiscal 2017.
- PFIZER INC proceeds from stock options exercised for fiscal 2017 was $862.00M, a 15.41% decline from fiscal 2016.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 3 month as first filed | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 6 month as first filed | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 9 month as first filed | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | $219.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $267.00M derived: sum of 2 quarters · filed 2021-02-25 | $301.00M derived: sum of 3 quarters · filed 2021-02-25 | $425.00M 10-K · filed 2021-02-25 | |||
| 2020-09-27 | $48.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $82.00M derived: sum of 2 quarters · filed 2020-11-05 | $206.00M 10-Q · filed 2020-11-05 | $297.00M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2020-06-28 | $34.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $158.00M 10-Q · filed 2020-08-06 | $249.00M derived: sum of 3 quarters · filed 2021-02-25 | $304.00M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2020-03-29 | $124.00M 10-Q · filed 2020-05-07 | $215.00M derived: sum of 2 quarters · filed 2021-02-25 | $270.00M derived: sum of 3 quarters · filed 2021-02-25 | $392.00M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-12-31 | $91.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $146.00M derived: sum of 2 quarters · filed 2021-02-25 | $268.00M derived: sum of 3 quarters · filed 2021-02-25 | $394.00M 10-K · filed 2021-02-25 | |||
| 2019-09-29 | $55.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $177.00M derived: sum of 2 quarters · filed 2020-11-05 | $303.00M 10-Q · filed 2020-11-05 | $463.00M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | $122.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $248.00M 10-Q · filed 2020-08-06 | $408.00M derived: sum of 3 quarters · filed 2021-02-25 | $1.03B derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $126.00M 10-Q · filed 2020-05-07 | $286.00M derived: sum of 2 quarters · filed 2021-02-25 | $911.00M derived: sum of 3 quarters · filed 2021-02-25 | $1.01B derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $160.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $785.00M derived: sum of 2 quarters · filed 2021-02-25 | $887.00M derived: sum of 3 quarters · filed 2021-02-25 | $1.26B 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $625.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $727.00M derived: sum of 2 quarters · filed 2019-11-07 | $1.10B 10-Q · filed 2019-11-07 | $1.30B derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-07-01 | $102.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $474.00M 10-Q · filed 2019-08-08 | $680.00M derived: sum of 3 quarters · filed 2020-02-27 | $925.00M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-04-01 | $372.00M 10-Q · filed 2019-05-09 | $578.00M derived: sum of 2 quarters · filed 2020-02-27 | $823.00M derived: sum of 3 quarters · filed 2020-02-27 | $921.00M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $206.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $451.00M derived: sum of 2 quarters · filed 2020-02-27 | $549.00M derived: sum of 3 quarters · filed 2020-02-27 | $862.00M 10-K · filed 2020-02-27 | |||
| 2017-10-01 | $245.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $343.00M derived: sum of 2 quarters · filed 2018-11-08 | $656.00M 10-Q · filed 2018-11-08 | $729.00M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-07-02 | $98.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $411.00M 10-Q · filed 2018-08-09 | $484.00M derived: sum of 3 quarters · filed 2019-02-28 | $734.00M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-04-02 | $313.00M 10-Q · filed 2018-05-10 | $386.00M derived: sum of 2 quarters · filed 2019-02-28 | $636.00M derived: sum of 3 quarters · filed 2019-02-28 | $1.04B derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2016-12-31 | $73.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $323.00M derived: sum of 2 quarters · filed 2019-02-28 | $723.00M derived: sum of 3 quarters · filed 2019-02-28 | $1.02B 10-K · filed 2019-02-28 | |||
| 2016-10-02 | $250.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $650.00M derived: sum of 2 quarters · filed 2017-11-09 | $946.00M 10-Q · filed 2017-11-09 | $1.04B derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2016-07-03 | $400.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $696.00M 10-Q · filed 2017-08-10 | $794.00M derived: sum of 3 quarters · filed 2018-02-22 | $978.00M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2016-04-03 | $296.00M 10-Q · filed 2017-05-11 | $394.00M derived: sum of 2 quarters · filed 2018-02-22 | $578.00M derived: sum of 3 quarters · filed 2018-02-22 | $765.00M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2015-12-31 | $98.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $282.00M derived: sum of 2 quarters · filed 2018-02-22 | $469.00M derived: sum of 3 quarters · filed 2018-02-22 | $1.26B 10-K · filed 2018-02-22 | |||
| 2015-09-27 | $184.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $371.00M derived: sum of 2 quarters · filed 2016-11-10 | $1.17B 10-Q · filed 2016-11-10 | $1.46B derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-06-28 | $187.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $981.00M 10-Q · filed 2016-08-11 | $1.28B derived: sum of 3 quarters · filed 2017-02-23 | $1.40B derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-03-29 | $794.00M 10-Q · filed 2016-05-12 | $1.09B derived: sum of 2 quarters · filed 2017-02-23 | $1.21B derived: sum of 3 quarters · filed 2017-02-23 | $1.37B derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2014-12-31 | $298.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $419.00M derived: sum of 2 quarters · filed 2017-02-23 | $577.00M derived: sum of 3 quarters · filed 2017-02-23 | $1.00B 10-K · filed 2017-02-23 | |||
| 2014-09-28 | $121.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $279.00M derived: sum of 2 quarters · filed 2015-11-05 | $704.00M 10-Q · filed 2015-11-05 | $1.08B derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-29 | $158.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $583.00M 10-Q · filed 2015-08-06 | $963.00M derived: sum of 3 quarters · filed 2016-02-29 | $1.16B derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-30 | $425.00M 10-Q · filed 2015-05-07 | $805.00M derived: sum of 2 quarters · filed 2016-02-29 | $1.00B derived: sum of 3 quarters · filed 2016-02-29 | $1.53B derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $380.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $575.00M derived: sum of 2 quarters · filed 2016-02-29 | $1.11B derived: sum of 3 quarters · filed 2016-02-29 | $1.75B 10-K · filed 2016-02-29 | |||
| 2013-09-29 | $195.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $728.00M derived: sum of 2 quarters · filed 2014-11-06 | $1.37B 10-Q · filed 2014-11-06 | $1.44B 10-Q · filed 2013-11-08 | $1.58B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-06-30 | $533.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $1.18B 10-Q · filed 2014-08-07 | $1.25B 10-Q · filed 2013-08-09 | $1.39B derived: sum of 3 quarters · filed 2015-02-27 | $1.54B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-03-31 | $642.00M 10-Q · filed 2014-05-08 | $688.00M 10-Q · filed 2013-05-10 | $855.00M derived: sum of 2 quarters · filed 2015-02-27 | $1.01B derived: sum of 3 quarters · filed 2015-02-27 | $1.18B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2012-12-31 | $213.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $370.00M derived: sum of 2 quarters · filed 2015-02-27 | $533.00M derived: sum of 3 quarters · filed 2015-02-27 | $568.00M 10-K · filed 2015-02-27 | |||
| 2012-09-30 | $157.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $320.00M derived: sum of 2 quarters · filed 2013-11-08 | $355.00M 10-Q · filed 2013-11-08 | ||||
| 2012-07-01 | $163.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $198.00M 10-Q · filed 2013-08-09 | |||||
| 2012-04-01 | $35.00M 10-Q · filed 2013-05-10 | ||||||
| 2011-12-31 | $153.00M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |